Yüklüyor......

Treatment with ibrutinib inhibits BTK and VLA-4 dependent adhesion of chronic lymphocytic leukemia cells in vivo

PURPOSE: Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells from lymphoid tissues into the blood. We therefore sought to investigate the in vivo effect of ibrutinib on migratio...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Herman, Sarah E. M., Mustafa, Rashida Z., Jones, Jade, Wong, Deanna H., Farooqui, Mohammed, Wiestner, Adrian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609275/
https://ncbi.nlm.nih.gov/pubmed/26089373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0781
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!